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BACKGROUND: Data collection for screen-detected breast cancer in the United Kingdom is fully funded, which has led to
improvements in clinical practice. However, data on symptomatic cancer are deficient, and the aim of this project was to monitor the
current practice.
METHODS: A data set was designed together with surrogate outcome measures to reflect best practice. Data from cancer registries
initially required the consent of clinicians, but in the third year anonymised data were available.
RESULTS: The quality of data improved, but this varied by region and only a third of the cases were validated by clinicians. Regional
variations in mastectomy rates were identified, and one-third of patients who underwent conservative surgery for the treatment
invasive breast cancer were not recorded as receiving radiotherapy.
CONCLUSION: National data are essential to ensure that all patients receive appropriate treatment for breast cancer, but variations still
exist in the United Kingdom and further improvement in data capture is required.
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The NHS Breast Screening Programme (NHSBSP), which was set
up in 1988 based on the strength of the Forrest Report (Forrest,
1986), has had a number of important effects. At that time, the
management of patients with breast cancer in the United Kingdom
lay in the hands of general surgeons and, although many took
special interest in the disease, the concepts of the breast care nurse
and the multi-disciplinary team (MDT) were yet to be introduced
in most hospitals. With the passage of time, the occasional
operator came to accept the fact that the overall management of
breast cancer required the attention of a dedicated team working
out of a specialty breast unit, and the disciplines required for the
screening process of specialist radiologists, surgeons and pathol-
ogists gradually took hold. However, the requirement for complete,
accurate and timely data took longer to gain acceptance.
The collection of data on screen-detected breast cancer was
funded from the outset by the NHSBSP, and has been facilitated by
a single, breast screening computer system. In addition, the
Regional Breast Screening QARCs (Quality Assurance Reference
Centres) have been instrumental in providing good-quality data
for audit (NHS Breast Screening Programme, 2008). The feedback
on variations in practice at annual audit meetings organised both
regionally and nationally, has identified outliers in clinical practice
and, although peer pressure has been proved to be a slow process
in establishing a consensus, it has been possible to show major
changes in clinical practice over time (Sauven et al, 2003). The
appointment of regional representatives for the screening pro-
gramme led to the formation of the Breast Group of the British
Association of Surgical Oncology (BASO), which in turn developed
into the Association of Breast Surgery at BASO (ABS), and the
presentation of NHSBSP/ABS audit data at the ABS Annual
Meeting has become the main focal point for breast surgeons in the
United Kingdom.
As the screening data became more robust, the lack of data for
the majority of breast cancers that present symptomatically
became more obvious, and with this recognition there was a
growing concern that variations in the standard of care and sub-
optimal practice might well be obscured. Since then, the lack of a
national breast cancer database has been a limiting factor;
although a BASO database was initially funded by Zeneca and
later by the Department of Health, the software included all breast
consultations and focussed on communication with the general
practitioner rather than on systematic data collection. As a result,
the database was not used widely and support was eventually
withdrawn.
In response to these concerns, in 2000, the ABS initiated
systematic data collection for symptomatic breast cancers and,
with the support of those units with good data collection systems,
achieved approximately one-third of the estimated national
caseload. However, it became apparent with each year of this
unfunded initiative that, as new units began submitting data, many
collaborators failed to continue, often because of the withdrawal of
funding for data managers. There was also a move by some acute
hospital trusts to meet their responsibility to provide cancer
waiting times data by extending the duties of established breast
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scancer data managers, which also had a negative effect. Over the
same period, the ACGBI (Association of Coloproctology of Great
Britain and Ireland) took a similar initiative to collect data on the
management of colorectal cancer, and more recent attempts to
collect data on oesophago-gastric and thyroid cancers by the
respective professional associations (the Association of Upper
Gastrointestinal Surgeons (AUGIS) and the British Association of
Endocrine and Thyroid Surgeons (BAETS)), have suffered the
same constraints, with retrieval rates of little more than a third of
the national data.
Therefore, it became clear that requests made to individual
clinicians or to units were not the right way forward, and in 2003 it
was suggested that the data held by the regional cancer registries
could be used to resolve the problem. Fears were expressed that
data collection was less than complete in some registries, and it
subsequently became apparent that permission for data release by
individual clinicians and the requirement for anonymisation might
be barriers to progress. It was at this stage that the Breast Cancer
Clinical Outcome Measures (BCCOM) Project was established
using a subset of the national breast cancer data set for maximising
the ability of regional cancer registries to participate. As it is
recognised that it takes some years before it becomes apparent
whether variations in treatment lead to differences in disease-free
and overall survival, a series of surrogate clinical outcome
measures or ‘key performance indicators’ has been developed to
monitor the extent to which best practice is followed.
METHODS
A breast cancer data set was designed after consultation with the
ABS and the UKACR (UK Association of Cancer Registries). Data
on all newly-diagnosed primary symptomatic breast cancers are
obtained from the UK cancer registries and include basic
demographic details, diagnostic information, tumour character-
istics and the type of surgical and adjuvant treatment for each case.
Male breast cancers are included, but screen-detected cases are
excluded as far as possible. To reduce the contamination of
symptomatic cases with screen-detected breast cancers, cases
flagged by cancer registries as screen-detected breast cancers (as
required in the national cancer registry peer review measures
(Department of Health, 2005)) are excluded from the BCCOM data
set. Cancer registries were asked to flag cases as having had a
pre-operative diagnosis of breast cancer if the case record
contained a cytology or core biopsy diagnosis that pre-dated the
first therapeutic operation.
To validate the accuracy of data collection, cancer registries send
the collected data to the concerned consultant breast surgeon. The
surgeons in turn are asked to check the validity of data by comparing
them with those held on local systems, to make amendments if
necessary and to return the data without patient-identifiable details
to the BCCOM Project team at the West Midlands Cancer
Intelligence Unit (WMCIU). Surgeons may submit unchecked data
if they do not have the necessary support mechanisms or if they are
convinced that the quality of the data is high. Cases are not included
if the surgeon attends less than six symptomatic cases in the year,
chooses not to participate or is unknown.
From year 2 onwards, the initial protocol for data collection was
modified to ensure compliance with Section 60 of the Health and
Social Care Act 2001. It was observed that, although non-
identifiable data were stored in the BCCOM central database, the
flow of information at the beginning of the audit cycle, from cancer
registry to surgeon for validation, was at an individual patient level.
Therefore, the updated protocol requested that cancer registries
obtain the written consent of individual consultant surgeons before
releasing the data to the lead breast surgeon in each hospital. In
year 2, all consultant breast surgeons, whether members of the ABS
or not, were invited to participate in the BCCOM audit. The
regional symptomatic surgical representatives contacted the lead
breast surgeon in each hospital, seeking his (or her) help in
collecting their colleagues’ written consent to release data. In year 3,
the process for data transfer from the cancer registries to the
relevant consultant surgeon was altered such that for all registries
apart from those in South West, Northern Ireland and Scotland, the
data were distributed by the BCCOM team at the WMCIU. In
addition, cancer registries provided the BCCOM team with data on
all the breast cancers diagnosed in each region for that audit year
(2004) so that an accurate denominator could be identified.
The data collected were analysed against the surrogate Clinical
Outcome Measures devised by the BCCOM steering group
(Table 1).
RESULTS
Recruitment
Table 2 shows participation levels in the BCCOM Project in each
region and country. In year 2 (cases diagnosed in 2003), there was
a 14% reduction in the total number of cases submitted (14120
compared with 16407) and very large reductions in some regions.
These decreases are in part because of the more reliable exclusion
of ineligible screen-detected cases in year 2, but mainly result from
changes in the protocols for data collection in year 2, which
required written consent from all surgeons before releasing the
data of patients under their care to the lead surgeon in each
hospital for validation. In year 3 (cases diagnosed in 2004), the UK
cancer registries supplied the BCCOM team with data on all 48983
diagnosed breast cancers. This provided a denominator of the total
number of eligible cases with which participation could be
compared (Table 3) and an estimate of the annual breast cancer
burden in the United Kingdom could be made. Wales had the
highest recruitment of cases at 94%, and the Thames Region,
which has the highest number of surgeons and the most number of
cases, had by far the lowest recruitment at 29%. Figure 1 shows
that, in addition to the 1219 cases (3%), which were excluded in
year 3 because the surgeon had treated fewer than six symptomatic
cases, a further 21220 symptomatic cases (54% of the total number
of symptomatic cases identified by the cancer registries) could not
be included either because the surgeon was non-compliant (15471
cases) or unknown (5749 cases).
Table 1 Surrogate clinical outcome measures for breast cancer
proposed by the BCCOM Project team
Proposed surrogate clinical outcome measures
1. Number and proportion of breast cancers for which complete information is
received
2. Number of symptomatic and screen-detected breast cancers treated in a
hospital per annum
3. Number and proportion of breast cancers for which there is a pre-operative
diagnosis
4. Number and proportion of breast cancers given medical treatment only
5. Number and proportion of breast cancers treated surgically
6. Mastectomy rate by breast size: o15; X15 and p20; 420 and p35; 435
and p50; 450mm invasive diameter
7. Number and proportion of invasive breast cancers for which nodal status is
known
8. Number and proportion of histologically node-negative invasive breast
cancers for which more than seven nodes were harvested
9. Number and proportion of invasive breast cancers treated by breast-
conserving surgery and receiving radiotherapy
10. Number and proportion of node-positive patients with invasive breast
cancers, aged o60 years, receiving chemotherapy
11. Number and proportion of patients with ER-positive invasive breast cancers,
receiving hormone therapy
BCCOM¼breast cancer clinical outcome measure; ER¼oestrogen receptor.
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sIn year 3 (cases diagnosed in 2004), 16611 female breast cancers
were included and 128 breast cancers were detected in men.
Slightly more breast cancers presented in the left breast (52 vs
48%). A total of 25% of cases were diagnosed in patients aged o50
years, 28% in those aged 50–64, 9% in those aged 65–69 and 37%
in patients aged 70 or older.
Screening flag
In year 3 (cases diagnosed in 2004), of the 48983 breast cancers cases
registered by cancer registries, 9805 (20%) were flagged as screen
detected (Figure 1). From the NHSBSP/ABS audit of screen-detected
cancers, it is known that 14057 cases would have had a date of first
offered appointment to screening in 2004, indicating that the cancer
registries had accurately assigned only 70% of the screen-detected
cases. Those regions that did not have the robust communications
between cancer registries and breast screening QA reference centres,
which are required to flag screen-detected breast cancers accurately,
tended to have the highest rates of non-invasive breast cancers (up to
10% in year 1) and the greatest proportion of cases in the then
screening age group (50–64 years) included in their BCCOM
cohorts. The proportion of non-invasive breast cancers decreased
from 6.3% in year 1 to 5.8% in year 3, but this rate is still higher than
that expected from the literature, which suggests that only 3% of
non-invasive breast cancers present symptomatically (Blamey et al,
2000) compared with 21% (including micro-invasion) of screen-
detected cases (NHS Breast Screening Programme, 2008). This
provides surrogate evidence of continuing contamination by screen-
detected breast cancers in some regions. The recent requirement of
the national cancer registry peer review measures for registries to
obtain details of screen-detected breast cancers from breast screen-
ing QA reference centres has greatly improved the situation
compared with that of 2003, and it is hoped that in year 4 (cases
diagnosed in 2005), all registries will have correctly identified their
screen-detected cases.
Histological type
Of the 47266 breast cancer cases that were submitted to BCCOM
during years 1–3, invasive ductal carcinoma was the most
common histological type (68%), followed by invasive lobular
carcinoma (12%), ductal carcinoma in situ (5%), mixed invasive
carcinoma (5%), mucinous carcinoma (2%) and tubular carcino-
ma (1%). These proportions will probably change slightly when all
screen-detected cases have been eliminated, but they illustrate how
the audit could provide a source of a relatively large number of
rarer tumours for research.
Nodal status
Of the breast cancer cases submitted in year 3 (cases diagnosed in
2004), 31.8% were lymph node positive, 34.3% were lymph node
negative and 33.9% had unknown nodal status (Table 4). For surgically
treated cases, 40.5% were lymph node positive, and the proportion with
Table 2 Participation by regions and Celtic countries in years 1, 2 and 3 of the BCCOM project
Diagnosis year
2002 2003 2004 2002–2004
Region or Celtic country BCCOM year 1 BCCOM year 2 BCCOM year 3 Total % eligible cases year 3
Eastern 1691 997 1507 4195 65
North West 1091 524 1397 3012 41
Northern and Yorkshire 2419 2029 1910 6358 52
Northern Ireland 640 367 432 1439 45
Oxford 1341 1442 899 3682 62
Scotland 934 181 1836 2951 49
South West 3253 1001 2234 6488 54
Thames 1750 2709 1530 5989 29
Trent 408 1588 1453 3449 52
Wales 351 952 1201 2504 94
West Midlands 2529 2330 2340 7199 77
Total 16407 14120 16739 47266 52
BCCOM¼breast cancer clinical outcome measure.
Table 3 Participation by surgeons in year 3 of the BCCOM project (cases diagnosed in 2004)
Eligible surgeons
a Eligible surgeons who submitted data Take up BCCOM year 3
Region or Celtic
country
Number of
surgeons
Number
of cases
Average, cases/
surgeon
Number of
surgeons
Number
of cases
Average, cases/
surgeon
% of eligible
surgeons
% of eligible
cases
Eastern 42 2314 55 15 1507 100 35.7 65.1
North West 66 3442 52 20 1397 70 30.3 40.6
Northern and Yorkshire 55 3692 67 25 1910 76 45.5 51.7
Northern Ireland 16 962 60 6 432 72 37.5 44.9
Oxford 18 1447 80 12 899 75 66.7 62.1
Scotland 46 3767 82 30 1836 61 65.2 48.7
South West 56 4121 74 27 2234 83 48.2 54.2
Thames 77 5283 69 18 1530 85 23.4 29.0
Trent 35 2782 79 15 1453 97 42.9 52.2
Wales 28 1276 46 18 1201 67 64.3 94.1
West Midlands 49 3027 62 35 2340 67 71.4 77.3
Total 488 32113 66 221 16739 76 45.3 52.1
BCCOM¼breast cancer clinical outcome measure.
aSurgeons were eligible if they treated 6 or more symptomatic breast cancer cases in 2004.
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sunknown lymph node status was 14.4%. The relatively high proportion
of surgically treated cases with unknown lymph node status may be
because of the fact that some cancer registries do not record data on
lymph node status and tumour size for patients who receive
neoadjuvant chemotherapy or radiotherapy. This is because the use
of such data to determine the Nottingham Prognostic Index (NPI)
(Haybittle et al, 1982) or the pathological TNM stage at diagnosis could
result in an inaccurate under-staging of the cancer. Recording of the
axillary node status increased during years 2–3 of the audit for all age
groups, but was higher in those under the age of 50 years (89%) than in
those aged over 80 (72%), largely because the latter group are less likely
to undergo surgery.
Tumour size
In year 3, for 31.4% of the cancers included in the cohort, the
maximum diameter of the invasive tumour component was
o20mm, and for 24.6% of cases the invasive size was unknown.
For surgically treated cases, the invasive tumour size was unknown
for only 7% of cancers. In most of the latter cases, the invasive size
at diagnosis was not recorded either because the patient had
received neoadjuvant treatment, which may have reduced the
original size at diagnosis, or because the tumour was removed in
several pieces from more than one operation.
Tumour grade
In year 3, 12.0% of invasive cancers were classified as grade 1, 41.0%
were grade 2 and 33.2% were grade 3. For surgically treated cases,
these proportions were 12.8, 43.3 and 37.9% respectively. The grade
was unknown for 13.9% of all cases, but this decreased to 6.0% for
surgically treated cases. Pathologists are reluctant to report the grade
of the tumour after neoadjuvant treatment, which may partly explain
the latter shortfall. There was little variation in tumour grade over
the 3 years of the study. There was a clear association between nodal
status, tumour grade and size; with grade 1 cancers being smaller
and more likely to be node negative (Figure 2).
Nottingham prognostic index
In year 3, the NPI score could be calculated for 80% of the
surgically treated invasive breast cancers. The NPI could not be
calculated in 20% of the cases because of missing grade (6%), size
(7%) and/or nodal status (14%). Nodal status was not available in
28% of patients over the age of 80 years. Among those cases with a
known NPI, 51% were early breast cancers with an NPI score of
below 4.4 and were categorised into the Excellent Prognostic
Group (EPG), Good Prognostic Group (GPG) or Moderate
Prognostic Group 1 (MPG1). Overall, 49% were categorised into
the MPG2 or Poor Prognostic Group (PPG) (Blamey et al, 2007).
These data are in marked contrast to screen-detected breast
cancers. In the NHSBSP/ABS audit of screen-detected breast
cancers that were diagnosed in 2004, 83% of cases had an NPI
score of below 4.4 (24% in the EPG, 36% in the GPG and 22% in
the MPG1), 11% were in the MPG2 and 6% in the PPG. The
variation in NPI with age at diagnosis for surgically treated screen-
detected and symptomatic breast cancers is shown in Figure 3.
Surrogate clinical outcome measures
The surrogate clinical outcome measures proposed by the BCCOM
Project team are shown in Table 1. The number of cases treated in
each breast unit cannot be calculated from BCCOM data as not all
surgeons agreed to participate in the audit. Pre-operative diagnosis
rates varied between 12% in Scotland and 87% in the West
Midlands and were 40% or less in five regions. The NHSBSP/ABS
Cases submitted by 
surgeon
16 739
Cases not sent 
back by surgeon
5962
Surgeon did not sign 
consent form
8114
Surgeon could not 
be contacted
1395
Surgeon not invited 
as treated less than 6 
symptomatic cases
1219
Total number of primary breast
cancers diagnosed in 2004
48 983
Symptomatic
39 178
Screen-detected
9805
Treating surgeon agreed to 
take part (signed consent 
form)   22 701
No consent form 
signed 
10 728
Unknown 
surgeon
5749
No surgeon and no 
hospital assigned
909
No surgeon 
assigned but 
hospital known
4840
Figure 1 Total number of breast cancers recorded in BCCOM year 3 (cases diagnosed in 2004).
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saudit of screen-detected breast cancer has shown an improvement
in pre-operative diagnosis from 63% between 1996 and 1997 to
94% between 2006 and 2007 (NHS Breast Screening Programme,
2008). Reliable pre-operative diagnosis data were only available
from at most three cancer registries, because many of them record
data only from pathology reports for resection specimens and do
not record details from any preceding cytology or core biopsy
reports. The numbers of nodes reported in what proved to be a
negative sample are shown in Figure 4. In those patients treated
with breast-conserving surgery, the majority with negative axillae
had eight or more nodes reported.
Surgical treatment
Variations in the treatment of invasive cancers with age at diagnosis in
year 3 are shown in Figure 5. The proportion of women not receiving
surgery increased with age from 3.5% in women aged o50 years to
47.7% in women aged 80 or more. The proportion receiving breast-
conserving surgery decreased with age from 51.4% in women aged
o65 years to 41.9% in women aged 65 or more. For surgically treated
cases, in each region, the breast-conserving surgery rate was higher in
younger patients, but this difference between age groups was most
marked in Oxford (58 vs 43%) and in Wales (54 vs 26%). The
proportion of cases receiving breast-conserving surgery was lower
than the UK average of 47.6% in Trent, Northern Ireland and
Northern and Yorkshire and was higher than the UK average in the
Thames Region. Figure 6 shows the regional variation in the operation
types recorded for invasive breast cancers with a diameter o15mm.
At 42%, the Trent Region had the highest mastectomy rate for this
g r o u po fs m a l lt u m o u r s ,a n dN o r t h e r nI r e l a n da n dt h eN o r t hW e s t
Region the lowest (19 and 23% respectively). However, as the
proportion of cases with unknown operation type was high in these
areas, care should be taken in the interpretation of these reported
patterns of care.
Adjuvant treatment
Figure 7 shows, for all breast cancer patients with known adjuvant
therapy included in BCCOM years 1–3, how the proportions of
cases receiving adjuvant radiotherapy, chemotherapy and hor-
mone therapy vary with age at diagnosis. The recorded use of
hormone therapy increases with age, with 85.6% of patients aged
80 years and more receiving hormone therapy compared with
66.4% of patients aged o50 years. This older age group is less
likely to receive surgical intervention, and as such hormone
therapy may be the only form of active treatment provided. In
contrast, the recorded use of radiotherapy decreases with
increasing age. In total, 78.3% of the patients aged o50 years
received radiotherapy compared with 30.6% of patients aged over
80. The effect of age on recorded treatment modality is most
marked for chemotherapy, where 77.2% of patients aged o50
received chemotherapy, but only 21.9% of patients aged 65–79 and
16% of patients aged 65 and more.
In the 3-year period between 2002 and 2004, radiotherapy was
recorded as having been received by 68.7% of the 16487 patients
included in the audit who were treated with conservative surgery.
Table 4 Characteristics of the invasive breast cancers included in year 3
of the BCCOM Project (cases diagnosed in 2004)
Invasive breast
All invasive (15540)
Surgically
treated only
(11725)
cancers diagnosed
in 2004
No. of
cases %
% (when
known)
No. of
cases %
% (when
known)
Nodal status
Positive 4941 31.8 48 4754 40.5 47
Negative 5332 34.3 52 5287 45.1 53
Unknown 5267 33.9 NA 1684 14.4 NA
Grade
I 1862 12.0 14 1501 12.8 14
II 6371 41.0 48 5073 43.3 46
III 5152 33.2 38 4449 37.9 40
Unknown 2155 13.9 NA 702 6.0 NA
Invasive size
o15mm 2544 16.4 22 2360 20.1 22
15–o20mm 2340 15.1 20 2220 18.9 20
20–o50mm 5862 37.7 50 5472 46.7 50
50+mm 968 6.2 8 849 7.2 8
Unknown 3826 24.6 NA 824 7.0 NA
NPI
EPG+GPG+MPG1 4896 31.5 51 4816 41.1 51
MPG2 + PPG 4673 30.1 49 4567 39.0 49
Unknown 5971 38.4 NA 2342 20.0 NA
Surgery
Breast-conserving surgery 5583 35.9 41 5583 47.6 NA
Mastectomy 6142 39.5 45 6142 52.4 NA
No surgery 2034 13.1 15 NA NA NA
Unknown 1781 11.5 NA NA NA NA
BCCOM¼breast cancer clinical outcome measure; EPG¼ Excellent Prognostic
Group; GPG¼ Good Prognostic Group; MPG1¼ Moderate Prognostic Group 1;
MPG2¼ Moderate Prognostic Group 2; NPI¼ Nottingham Prognostic Index;
PPG¼ Poor Prognostic Group.
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Figure 2 Variation in lymph node status with tumour grade and size for tumours included in BCCOM years 1–3.
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sA total of 1126 cases (6.8%) were recorded as not having received
radiotherapy, but for a further 4029 cases (24.4%), it was not
known whether radiotherapy was given. Fewer elderly patients
were recorded as having undergone radiotherapy after conserva-
tive surgery, with the proportion known to have received
radiotherapy decreasing from 70% in patients aged under 50 years
to 43% in those aged 80 and above.
In the 3-year period of 2002–2004, chemotherapy was recorded as
having been received by 53% of the 13100 patients with invasive
breast cancer who were node positive( F i g u r e8 ) .At o t a lo f2 6 3 0c a s e s
(20.1%) were recorded as not having received chemotherapy and for a
further 3524 cases (26.9%), it was not known whether chemotherapy
was given. In node-positive patients under the age of 70 years, the
proportion known to have received adjuvant chemotherapy was 68%
compared with only 12% in those aged 70 or more.
Of the cases with known hormone treatment that were receptor
positive (oestrogen receptor (ER) positive and/or progesterone
receptor), 11% (1241 cases) did not receive any form of hormone
treatment. For 16% (2418 cases) of the receptor-positive invasive
cancers, it was not known whether hormone treatment was given.
Only 3961 cases were receptor negative and of these, 9% (367
cases) were known to have been prescribed hormone therapy. Of
the 5112 invasive breast cancer cases who did not undergo surgery,
3106 (61%) were recorded as having received hormone therapy,
but only 2176 (43%) had known ER status. It would be anticipated
that the majority of these mostly elderly patients, who did not
Screen-detected
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Figure 3 Variation in Nottingham Prognostic Index (NPI) with age group for breast cancers diagnosed in 2004. Sources: screen-detected breast cancers
included in the NHSBSP/ABS annual audits (2003–2004 and 2004–2005) of screen-detected breast cancer; symptomatic breast cancers included in
BCCOM year 3.
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Figure 4 Variation in the number of nodes reported in node-negative
patients in BCCOM years 1–3 who received breast-conserving surgery or
mastectomy.
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Figure 5 Variation in surgical treatment with age at diagnosis in BCCOM
year 3 (invasive cancers diagnosed in 2004).
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sundergo an operation, would have had strong contraindications to
surgery and would have been treated with hormonal therapy.
Unfortunately, for all cases for which hormone therapy data are
recorded, tamoxifen is not distinguished from aromatase inhibi-
tors and switches are not identified.
DISCUSSION
Participation by breast surgeons in the BCCOM Project is not
m a n d a t o r y ,b u ti ti ss t r o n g l ye n c o u raged by their professional body,
the ABS. Previous experience with the NHSBSP/ABS audit of screen-
detected breast cancers has shown that a regular audit of surgical
practice improves standards and highlights outliers, in which local
protocols are not in keeping with the accepted best practice (Sauven
et al, 2003). The regional symptomatic representatives of ABS are
encouraged to review participation in their own areas and to identify
ways in which this could be improved. Although progress in data
collection has been improved by central notification of surgeons in
most regions, the data in Figure 1 underline the continuing difficulty in
depending on the voluntary and active participation of individual
surgeons in the submission and validation of data. The surgeon does
not own the data, and although their written permission for the release
of patient details under their care has been a prerequisite of the
BCCOM audit to date, it seems clear that the collection of cases will not
approach completeness on this basis. Furthermore, patients are increa-
singly managed by a MDT rather than by an individual consultant
s u r g e o n ,w h ow i l lb ei n v o l v e di nt h ei n i t i a lm a n a g e m e n tp l a nb u tw h o
may have little or no responsibilityf o rt h es u b s e q u e n tt r e a t m e n t .
At a national level, cancer registry data are now matched to data
held in national data sets, such as Hospital Episode Statistics (HES).
From those cancer registries, which routinely compare their data with
those on HES, it has become apparent that the latter can provide
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Figure 6 Variation with region and Celtic country in the operations recorded for patients with small invasive breast cancers (invasive diameter o15mm)
in BCCOM year 3 (cancers diagnosed in 2004).
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Figure 7 Variation in adjuvant treatment with age at diagnosis for
BCCOM years 1–3. Cases for which it was not known whether a patient
had received treatment have been excluded. In the elderly patients,
hormone therapy was sometimes the sole primary treatment.
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Figure 8 Variation with age at diagnosis in the proportion of node-
positive breast cancer patients in BCCOM years 1–3 recorded as having
received chemotherapy. Cases or which it was not known whether a
patient had received chemotherapy have been excluded.
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suseful information on operations for which the pathology reports may
not have been transferred to or accessed by cancer registries because
no malignancy is reported. These include additional operations to
remove nodes that are negative for tumour deposits and repeat
operations on the breast, such as delayed reconstruction, which have a
benign pathological outcome. Most importantly, matching cancer
registration and HES data also allows the identification of surgeons
and hospitals for each type of treatment if these data have not been
collected by the cancer registry, thus increasing the number of cases
that can be returned to surgeons for checking.
It has been possible to derive the surrogate outcome measures
proposed by the BCCOM Project team for a high proportion of the
symptomatic breast cancers included in the audit. The surrogate
outcome measures developed to date are restricted, to an extent, by
the common data items available from all cancer registries. As yet,
quality-of-life data and/or patient-reported outcome measures have
been collected on a research basis only, but it is clear that they should
become part of the standard outcome measures in the future. The
inclusion of reconstruction after mastectomy as a key performance
indicator should also be considered, and it is hoped that the inclusion
of a surrogate outcome measure fort h i sa r e aw i l lb ep o s s i b l eo n c e
HES data are obtained for all breast cancer cases treated in England.
Regional variations in surgical practice, especially with respect
to mastectomy rates, have been highlighted in the BCCOM audit,
but variations in individual clinical practice are more difficult to
identify as data were collected by the hospital or unit (Moritz et al,
1997). The reasons for regional variations are unclear, but
mastectomy rates tend to be higher in rural areas and this
association is not confined to the United Kingdom (Craft et al,
1997; Gort et al, 2007). The data for 2002–2004 indicate that
patients with lymph node-negative disease had a large number of
nodes removed even when the surgical procedure was conservative
(Figure 4). This time period reflects practice before as well as
including the wide-scale introduction of sentinel lymph node
biopsy (SLNB) for which the audit protocol required a nodal
clearance for all patients undergoing SNLB, and future data should
show a change in this practice. Variations in practice style by
individual surgeons are well recognised (Craft et al, 1997; Hawley
et al, 2006), but in breast cancer, any consequent variation in
patient outcomes such as recurrence rates or overall survival rates
may take many years to become apparent (Purushotham et al,
2001). It is for this reason that surrogate clinical outcome measures
have been proposed to reflect best practice, in order that publication
of the data may try to persuade outliers to change their practice.
The place of radiotherapy after conservative surgery for invasive
breast cancer is well-established (Clarke et al, 2005), and yet there
is evidence that this treatment has been under-used. There may
occasionally be a good reason not to give post-operative radio-
therapy but, if the BCCOM data are correct, a third of such patients
did not undergo prophylactic treatment and a third of these would
be expected to develop local recurrence. The indications for
radiotherapy for patients with in situ breast cancer are less well
defined, but current variations in practice are not always based on
the available evidence (Dodwell et al, 2007). There is also concern
that 20% of patients with node-positive disease under the age
of 50 years did not receive adjuvant chemotherapy (Figure 7). There
is now a requirement that the treatment of all patients with breast
cancer should be considered at a multi-disciplinary meeting, and
any failure to consider an appropriate adjuvant treatment should be
a thing of the past. Reflection on performance data such as those
provided by audits such as BCCOM should assist local breast teams
in identifying any non-compliance with national practice in their
protocols and for facilitating the targeting of areas requiring
modifications to make them consistent with best clinical practice.
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